arrow
A

Alexey V. Danilov

city of hope medical center
H指数:40
被引数:7,019

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hodgkin lymphoma transformation in patients with chemotherapy-naïve chronic lymphocytic leukemia

化疗初治慢性淋巴细胞白血病患者中霍奇金淋巴瘤的转化

2026-09-260
OAAI
Long-term survival and cause-specific mortality after event-free survival at 24 months (EFS24) in mantle cell lymphoma: an international multicohort study

套细胞淋巴瘤在24个月无事件生存期(EFS24)后的长期生存和特定病因死亡率:一项国际多队列研究

2026-09-220
OAAI
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

套细胞淋巴瘤在序贯一线 bendamustine-rituximab 和二线 Bruton 酪氨酸激酶抑制剂治疗后的预后

2026-04-250
OAAI
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025

淋巴瘤管理的临床策略:2025年白血病、淋巴瘤和多发性骨髓瘤共识会议的建议

Cancer
IF5.1
2026-04-090
PRE
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study

美国多中心回顾性研究:浆细胞样淋巴瘤的预后与治疗

2026-03-230
OAAI
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

通过MYC抑制miR-29会导致转化性滤泡性淋巴瘤中CD40信号增强

Leukemia
IF13.4
2026-02-190
OA
Safety and efficacy of the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed non-Hodgkin lymphoma: results from a phase I trial

Shouse, G.; Chen, C.; Muir, A.; Popplewell, L.; Siddiqi, T.; Zain, J.; Herrera, A.F.; Danilova, O.; Roleder, C.; Wang, L.; et al. 在Richter’s transformation或transformed non-Hodgkin lymphoma患者中copanlisib与nivolumab联合治疗的安全性与有效性:一项I期临床试验结果。Haematologica 2025. [Google Scholar] [CrossRef]

2026-01-013
OA
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma

利妥昔单抗维持治疗在一线苯达莫司汀联合利妥昔单抗治疗后滤泡性淋巴瘤患者中的获益

2025-12-150
OAAI
Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine

体液和功能性的SARS-CoV-2特异性T细胞反应,在慢性淋巴细胞白血病患者中通过GEO-CM04S1这一合成MVA载体COVID-19疫苗所诱导

2025-12-010
OAAI
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
2025-11-010
OA
Outcomes of Bispecific Antibodies After CAR T-Cell Failure for Large B-cell Lymphoma- Results from the ABC Consortium

大B细胞淋巴瘤在CAR T细胞治疗失败后使用双特异性抗体的疗效——ABC Consortium研究的结果

2025-10-240
OAAI
Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

门诊Brexucabtagene autoleucel在B细胞急性淋巴细胞白血病和套细胞淋巴瘤中的应用

2025-08-200
PREAI
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

与化疗免疫疗法、mosunetuzumab 或 odronextamab 在滤泡性淋巴瘤中的 epcoritamab 间接比较

2025-06-090
OA